Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era

BACKGROUND: Recent phase III studies of targeted agents for metastatic renal cell carcinoma (mRCC) have generated median survival estimates that far exceed those observed during the cytokine era. However, substantial population-based data does not exist to confirm this trend. We sought to determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Sumanta K., Nelson, Rebecca A., Vogelzang, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643924/
https://www.ncbi.nlm.nih.gov/pubmed/23658823
http://dx.doi.org/10.1371/journal.pone.0063341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643924/
https://www.ncbi.nlm.nih.gov/pubmed/23658823
http://dx.doi.org/10.1371/journal.pone.0063341

Ejemplares similares